You are here

One-day Behavioral Intervention for Patients with Inflammatory Bowel Disease and Co-Occurring Psychological Distress.

Related Articles One-day Behavioral Intervention for Patients with Inflammatory Bowel Disease and Co-Occurring Psychological Distress. Clin Gastroenterol Hepatol. 2017 May 19;: Authors: Hou JK, Vanga RR, Thakur E, Gonzalez I, Willis D, Dindo L PMID: 28532699 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/28532699?dopt=Abstract

Read More

Caregiver Burden in Adults with Inflammatory Bowel Disease.

Related Articles Caregiver Burden in Adults with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017 May 18;: Authors: Shukla R, Thakur E, Bradford A, Hou JK Abstract Inflammatory bowel disease (IBD) is a chronic condition which has a relapsing and remitting disease course. There is high degree of inpatient and outpatient health care utilization by IBD patients along with a great deal of psychosocial stress associated with the condition. Patients frequently rely on family, friends and other informal caregivers to provide medical, instrumental and emotional support. The role of caregiving for…

Read More

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients with Crohn’s Disease.

Related Articles Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients with Crohn’s Disease. Clin Gastroenterol Hepatol. 2017 Mar 29;: Authors: Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W Abstract BACKGROUND & AIMS: Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23, is an effective treatment for patients with Crohn’s disease (CD). Trough concentrations of tumor necrosis factor (TNF) antagonists and presence of anti-drug antibodies are associated with important clinical and endoscopic outcomes….

Read More
<< Go Back